Weekly Digest – 25-31 Mar 2023 Weekly Digest – 25-31 Mar 2023 30 Mar 2023: Opdivo (Nivolumab) (IV) / Neoadjuvant NSCLC / BMS: Long-term clinical benefits were observed in 3 years follow up in CheckMate -816 study The CheckMate -816 trial […]
Weekly Digest – 25-31 Mar 2023 Weekly Digest – 25-31 Mar 2023 27 Mar 2023: KEYTRUDA (Pembrolizumab) (IV) / Stage III-IV or 1L Endometrial Carcinoma / Merck: Improved Progression-Free Survival in Phase 3 trial Merck’s Phase 3 trial results of […]
Weekly Digest – 25-31 Mar 2023 Weekly Digest – 25-31 Mar 2023 27 Mar 2023: Kisqali (Ribociclib) / HR+/HER2- Early Breast Cancer / Novartis: Phase 3 Pivotal NATALEE trial meets primary endpoint of Invasive Disease-free survival Novartis announced encouraging data […]
